Blog
Concert Pharmaceuticals Plans CTP-543 Phase 3 trials in Alopecia Areata
Concert Pharmaceuticals is planning to proceed with its Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. “Our intent is to initiate the Phase 3 program of CTP-543 in the fourth quarter of 2020, pending COVID-19 to bring an important new treatment option to people living with this life-altering autoimmune disease.” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. Alopecia areata may affect up to 650,000 Americans at any given time. The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.
Related Posts
Whatever Happened to Hair Cloning?
New Hope for Teens Facing Sudden Hair Loss
Is Finasteride Finally Losing Its Grip?
Inside the New Drug Pipeline
Leqselvi – FDA Approved for Severe Alopecia Areata
Stress Re-Confirmed as a Major Factor in Hair Loss
FDA Halts Trial of Hair Loss Drug
Are you Keeping Your Customers Safe?
Finasteride Spray Expanding
COVID-19 Patients Suffer Hair Loss
FDA Approves First Systemic Treatment for Alopecia Areata
83 Yrs. and Growing Hair!
8 thoughts on “Concert Pharmaceuticals Plans CTP-543 Phase 3 trials in Alopecia Areata”
Click here to cancel reply.
You must be logged in to post a comment.
FDA will have to continue with this research
FDA will have to continue with this research
good step
Kudos
this work is good for people who are suffering from this kind of disease
Hope will hear the good news in forth quarter.
Keep it up! good initiative
Bravo!